Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, single dose study to determine the safety of valoctocogene roxaparvovec (an Adenovirus-Associated Virus (AAV) based gene therapy vector) in severe Hemophilia A patients with pre-existing antibodies against AAV5.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
3 participants in 1 patient group
Loading...
Central trial contact
Trial Specialist
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal